This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
bladder-cancer
Bladder Cancer
Urothelial carcinoma of the bladder; FGFR3 mutations in ~25-35% and TERT promoter mutations in ~75%; PD-L1 expression guides immunotherapy. BCG is standard for non-muscle-invasive disease; enfortumab vedotin + pembrolizumab is first-line for metastatic urothelial carcinoma.
Entry Metadata
| Field | Value |
|---|---|
| ID | bladder-cancer |
| Name | Bladder Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-1026. · PubMed 28212060
- Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875-888. · PubMed 38261487
- Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348. · PubMed 31340094